Methods: Using the PrEP continuum as framework, we used IDPH databases and UI medical records to conduct a retrospective process evaluation of the TelePrEP model (Feb 2017-Apr 2018).
Results: TelePrEP received 44 referrals from public health and 59 self-referrals via advertising. Pharmacists completed 84 initial visits (81% of referrals), including 37 visits (84%) with clients referred by public health. Most (94%) started emtricitabine/tenofovir after initial visits. Retention in TelePrEP at 6 months was 87%. 96% of guideline-indicated lab tests (HIV, creatinine, STI, hepatitis) were completed at baseline and follow up. Rates of extragenital chlamydia and gonorrhea screening were lower (74 of 104 completed screens) due to variable availability of swabs at local labs. 15 clients were diagnosed with 20 STIs on screening (6 syphilis, 4 gonorrhea, 10 chlamydia) and one unrecognized pregnancy was identified. PS linked all clients with STIs on screens to treatment within 14 days (80% in 3 days).
Conclusion: Using telemedicine, healthcare systems can partner with public health administered STI clinics and PS programs to create virtual PrEP delivery models in rural settings. Public health partnerships enhance client identification and ensure linkage to care for new STI diagnoses in telemedicine programs.
Gilead Sciences, Inc:
Research team member
D. Dillon, None
C. Scheetz, None
S. Owens, None
K. Edel, None
M. Ohl, Gilead Sciences, Inc: Grant Investigator , Research grant .